Mesenchymal Stem Cells in Preclinical Infertility Cytotherapy: A Retrospective Review
- PMID: 34054970
- PMCID: PMC8143877
- DOI: 10.1155/2021/8882368
Mesenchymal Stem Cells in Preclinical Infertility Cytotherapy: A Retrospective Review
Abstract
Infertility is a global reproductive disorder which is caused by a variety of complex diseases. Infertility affects the individual, family, and community through physical, psychological, social and economic consequences. The results from recent preclinical studies regarding stem cell-based therapies are promising. Stem cell-based therapies cast a new hope for infertility treatment as a replacement or regeneration strategy. The main features and application prospects of mesenchymal stem cells in the future of infertility should be understood by clinicians. Mesenchymal stem cells (MSCs) are multipotent stem cells with abundant source, active proliferation, and multidirectional differentiation potential. MSCs play a role through cell homing, secretion of active factors, and participation in immune regulation. Another advantage is that, compared with embryonic stem cells, there are fewer ethical factors involved in the application of MSCs. However, a number of questions remain to be answered prior to safe and effective clinical application. In this review, we summarized the recent status of MSCs in the application of the diseases related to or may cause to infertility and suggest a possible direction for future cytotherapy to infertility.
Copyright © 2021 Zhuo Chang et al.
Conflict of interest statement
The authors have no conflict of interest related to the preparation and submission of this review.
Similar articles
-
Mesenchymal Stem Cell-based Therapy and Female Infertility: Limitations and Advances.Curr Stem Cell Res Ther. 2023;18(3):322-338. doi: 10.2174/1574888X17666220511142930. Curr Stem Cell Res Ther. 2023. PMID: 35546752
-
Exploring the future potential of mesenchymal stem/stromal cells and their derivatives to support assisted reproductive technology for female infertility applications.Hum Cell. 2023 Sep;36(5):1604-1619. doi: 10.1007/s13577-023-00941-3. Epub 2023 Jul 5. Hum Cell. 2023. PMID: 37407748 Review.
-
A collagen scaffold loaded with human umbilical cord-derived mesenchymal stem cells facilitates endometrial regeneration and restores fertility.Acta Biomater. 2019 Jul 1;92:160-171. doi: 10.1016/j.actbio.2019.05.012. Epub 2019 May 7. Acta Biomater. 2019. PMID: 31075515
-
[Mesenchymal stem cells for the treatment of male infertility].Zhonghua Nan Ke Xue. 2020 Jun;26(6):564-569. Zhonghua Nan Ke Xue. 2020. PMID: 33356048 Review. Chinese.
-
Stem cells technology as a platform for generating reproductive system organoids and treatment of infertility-related diseases.Cell Biol Int. 2022 Apr;46(4):512-522. doi: 10.1002/cbin.11747. Epub 2021 Dec 30. Cell Biol Int. 2022. PMID: 34918417 Review.
Cited by
-
Improving Fertility in Non-obstructive Azoospermia: Results from an Autologous Bone Mar-row-Derived Mesenchymal Stromal/Stem Cell Phase I Clinical Trial.Int J Fertil Steril. 2024 Jul 13;18(Suppl 1):60-70. doi: 10.22074/ijfs.2023.2005045.1480. Int J Fertil Steril. 2024. PMID: 39033372 Free PMC article.
-
Bone marrow mesenchymal stem cells expressing Neat-1, Hotair-1, miR-21, miR-644, and miR-144 subsided cyclophosphamide-induced ovarian insufficiency by remodeling the IGF-1-kisspeptin system, ovarian apoptosis, and angiogenesis.J Ovarian Res. 2024 Sep 12;17(1):184. doi: 10.1186/s13048-024-01498-x. J Ovarian Res. 2024. PMID: 39267091 Free PMC article.
-
Proof-of-Concept for Long-Term Human Endometrial Epithelial Organoids in Modeling Menstrual Cycle Responses.Cells. 2024 Nov 2;13(21):1811. doi: 10.3390/cells13211811. Cells. 2024. PMID: 39513919 Free PMC article.
-
Human Umbilical Cord-Based Therapeutics: Stem Cells and Blood Derivatives for Female Reproductive Medicine.Int J Mol Sci. 2022 Dec 14;23(24):15942. doi: 10.3390/ijms232415942. Int J Mol Sci. 2022. PMID: 36555583 Free PMC article. Review.
-
Stem cell-based therapy for human diseases.Signal Transduct Target Ther. 2022 Aug 6;7(1):272. doi: 10.1038/s41392-022-01134-4. Signal Transduct Target Ther. 2022. PMID: 35933430 Free PMC article. Review.
References
-
- Liang G., Zhu Q., He X., et al. Effects of oil-soluble versus water-soluble contrast media at hysterosalpingography on pregnancy outcomes in women with a low risk of tubal disease: study protocol for a randomised controlled trial. BMJ Open. 2020;10(10, article e039166) doi: 10.1136/bmjopen-2020-039166. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous